Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.44 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | LPL | P06858 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | F11 | P03951 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 2/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4549875 | 0.96 | BACE1 (0.44) | BACE1BACE2PRMT5WDR77AAK1 | |
| SCHEMBL17645721 | 0.84 | ROCK1 (0.44) | BACE1BACE2ROCK1HIF1ADGAT1 | |
| SCHEMBL4549947 | 0.82 | AAK1 (0.49) | BACE1BACE2PRMT5WDR77AAK1 | |
| SCHEMBL2147588 | 0.81 | ROCK1 (0.43) | ROCK1DGAT1LIPGRORC | |
| SCHEMBL2036558 | 0.80 | PRMT5 (0.43) | BACE1BACE2PRMT5WDR77AAK1 | |
| SCHEMBL2699886 | 0.80 | ROCK1 (0.43) | BACE1BACE2ROCK1HIF1ADGAT1 | |
| SCHEMBL28506049 | 0.79 | LPL (0.43) | BACE1BACE2ROCK1LPLLIPG | |
| SCHEMBL65795 | 0.78 | AAK1 (0.49) | BACE1BACE2PRMT5WDR77AAK1 | |
| SCHEMBL5517439 | 0.78 | AAK1 (0.45) | BACE1AAK1USP30PDE2ADPP8 | |
| SCHEMBL34469713 | 0.78 | AAK1 (0.45) | BACE1AAK1USP30PDE2ADPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3204382-B1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-12-01 | — | — | EP | disclosed |
| US-20190233417-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
| US-20190233417-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
| US-10253023-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-04-09 | — | — | US | disclosed |
| US-10253023-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-04-09 | — | — | US | disclosed |
| EP-3204382-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016057500-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016057500-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-14 | — | — | WO | disclosed |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | US | disclosed |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | US | disclosed |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253023-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | BTK, SYK, LYN | BACE1 4437/4885BACE2 3422/4885PRMT5 2178/4885 |
| US-20190233417-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LYN | BACE1 4537/4885BACE2 3973/4885PRMT5 2913/4885 |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LYN | BACE1 4437/4885BACE2 3422/4885PRMT5 2178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.